Journal of Clinical Oncology, Vol 16, 1060-1067, Copyright © 1998 by American Society of Clinical Oncology
Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung
M Adachi, T Taki, C Huang, M Higashiyama, O Doi, T Tsuji and M Miyake
Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
PURPOSE: We investigated the possible association between integrin alpha3
and motility-related protein (MRP-1), cluster of differentiation antigen 9
(CD9) gene expression in non-small-cell lung cancer (NSCLC) and evaluated
the prognostic significance of integrin alpha3 expression. PATIENTS AND
METHODS: We performed a retrospective study of integrin alpha3 and
MRP-1/CD9 expression in resected tumor tissues from 151 NSCLC patients
using quantitative reverse-transcriptase polymerase chain reaction (RT-PCR)
and immunohistochemistry. RESULTS: The ratio of integrin alpha3/beta-actin
expression ranged from 0 to 5.87 (mean was 0.80; median, 0.70). Using the
cutoff value of 0.7, there were 78 (52%) integrin alpha3-positive tumors
and 73 (48%) tumors with reduced integrin alpha3 expression. The
immunohistochemical results agreed well with those of the RT-PCR assays,
and 88% had no discrepancy. In case of discrepancy, the results of RT-PCR
were used in specimen classification. Integrin alpha3 gene expression was
independent from MRP-1/CD9 gene expression. No significant association was
found between integrin alpha3 expression and the patients' clinical
characteristics. The overall survival rate of patients with integrin
alpha3-positive NSCLCs was only slightly better than that of individuals
whose tumors had reduced integrin alpha3 expression (55.9% v 47.1%; P =
.085). By comparison, the overall survival rate of patients with integrin
alpha3- positive adenocarcinomas was strikingly greater than in those whose
tumors had reduced gene expression (54.4% v 35.2%; P = .004). Multivariate
analysis with the Cox regression model of NSCLC and adenocarcinoma
indicated that integrin alpha3 expression correlated better (P = .0188 and
P = .0008, respectively) with the overall survival rate than other
variables, except lymph node status. CONCLUSION: No significant association
was found between integrin alpha3 and MRP-1/CD9 gene expression in lung
cancer. However, reduced integrin alpha3 expression is a poor prognosis
factor in patients with adenocarcinomas.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M C Boelens, A van den Berg, I Vogelzang, J Wesseling, D S Postma, W Timens, and H J M Groen
Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus
J. Clin. Pathol.,
June 1, 2007;
60(6):
608 - 614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wang, Z. Zhang, Z. Zhang, H. Vikis, Y. Yan, Y. Wang, and M. You
Fine Mapping and Candidate Gene Analyses of Pulmonary Adenoma Resistance 1, a Major Genetic Determinant of Mouse Lung Adenoma Resistance
Cancer Res.,
March 15, 2007;
67(6):
2508 - 2516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Spence, B. M. Duggan, C. Eckhardt, M. McClelland, and D. Mercola
Messenger RNAs under Differential Translational Control in Ki-ras-Transformed Cells
Mol. Cancer Res.,
January 1, 2006;
4(1):
47 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shintani, S. Higashiyama, M. Ohta, H. Hirabayashi, S. Yamamoto, T. Yoshimasu, H. Matsuda, and N. Matsuura
Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis
Cancer Res.,
June 15, 2004;
64(12):
4190 - 4196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bockhorn, S. Roberge, C. Sousa, R. K. Jain, and L. L. Munn
Differential Gene Expression in Metastasizing Cells Shed from Kidney Tumors
Cancer Res.,
April 1, 2004;
64(7):
2469 - 2473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa
Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer
Cancer Res.,
September 15, 2002;
62(18):
5210 - 5217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest,
September 1, 2002;
122(3):
1037 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Liu, C.-l. Huang, K. Kameyama, E. Hayashi, A. Yamauchi, S. Kobayashi, and H. Yokomise
E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer
Ann. Thorac. Surg.,
March 1, 2001;
71(3):
949 - 954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F Decline and P Rousselle
Keratinocyte migration requires alpha2beta1 integrin-mediated interaction with the laminin 5 gamma2 chain
J. Cell Sci.,
January 2, 2001;
114(4):
811 - 823.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. L. Lubman, X.-L. Zhang, J. Zheng, L. Ocampo, M. Z. Lopez, S. Veeraraghavan, S. M. Zabski, S. I. Danto, and Z. Borok
Integrin alpha 3-subunit expression modulates alveolar epithelial cell monolayer formation
Am J Physiol Lung Cell Mol Physiol,
July 1, 2000;
279(1):
L183 - L193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Fong, Y. Sekido, and J. D. Minna
MOLECULAR PATHOGENESIS OF LUNG CANCER
J. Thorac. Cardiovasc. Surg.,
December 1, 1999;
118(6):
1136 - 1152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sato, Y. Saijo, B. Uchiyama, N. Kumano, S.-i. Sugawara, S. Fujimura, M. Sato, M. Sagawa, K. Ohkuda, K. Koike, et al.
Prognostic Value of Nucleolar Protein p120 in Patients With Resected Lung Adenocarcinoma
J. Clin. Oncol.,
September 1, 1999;
17(9):
2721 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Krutzsch, B. J. Choe, J. M. Sipes, N.-h. Guo, and D. D. Roberts
Identification of an alpha 3beta 1 Integrin Recognition Sequence in Thrombospondin-1
J. Biol. Chem.,
August 20, 1999;
274(34):
24080 - 24086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
